<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095731</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA8597</org_study_id>
    <secondary_id>1R01FD003728-01</secondary_id>
    <nct_id>NCT01095731</nct_id>
  </id_info>
  <brief_title>The Effects of Tiopronin on 3-Aminopropanal Level &amp; Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage</brief_title>
  <official_title>Phase II Study of the Effects of Tiopronin on 3-Aminopropanal Level &amp; Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>E. Sander Connolly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal
      subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of
      tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this
      patient population.

      Funding Source - FDA Office of Orphan Products Development
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The annual rate of aSAH in United States is approximately 18 to 24 thousand cases each year.
      Mortality rates following aSAH range from 30-70% with 10-20% of survivors experiencing severe
      neurological disability. Following aSAH, a major cause of morbidity and mortality is
      vasospasm, which causes delayed ischemic neurologic deterioration. There is currently no
      effective treatment for preventing or ameliorating the damage that occurs following cerebral
      ischemia. A myriad of neuro-toxins are produced in the ischemic brain resulting in a vicious
      cycle of cellular death and destruction. The polyamines spermine and spermidine are
      metabolized by polyamine oxidase (PAO) into putrescine and 3-aminopropanal (3AP).

      Tiopronin (Thiola) is an FDA approved drug used for the treatment of cystine stones in
      patients with cystinuria in the U.S. In Europe, it is also used for the treatment of
      rheumatoid arthritis and bronchial hypersecretion. In previous animal studies, we
      demonstrated that tiopronin is able to bind and neutralize the toxic effects of 3AP. We have
      shown in previous studies that aSAH patients have elevated 3AP levels, and higher levels
      correlate to a poor neurologic outcome.

      The goals of this phase II multicenter, randomized, double-blinded safety and efficacy trial
      are to (1) further evaluate the safety of the drug in our patient population at the dose
      established in phase I; (2) demonstrate that tiopronin crosses the blood-brain barrier; (3)
      show that both serum and CSF 3AP levels are reduced by administration of tiopronin; and (4)
      demonstrate that a reduction in 3AP levels is associated with improved neurologic outcome in
      aSAH patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in CSF 3AP Levels</measure>
    <time_frame>Up to 14 days after SAH</time_frame>
    <description>CSF samples taken as a standard of care at each institution will be tested for routine parameters. A small portion of this sample will be saved and sent to Columbia University Medical Center to measure 3AP levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improve Neurological Outcome following aSAH</measure>
    <time_frame>Up to 12 months after discharge from hospital</time_frame>
    <description>Outcome assessments will include:
Modified Rankin Scale
Barthel Index
Lawton Physical Self Assessment Test (PSMS)
Lawton Instrumental Activities of Daily Living (IADL)
NIH Stroke Scale (NIHSS)
Telephone Interview Cognitive Status (TICS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improve Neurological Outcome following aSAH</measure>
    <time_frame>Up to 3 months after discharge from hospital</time_frame>
    <description>Outcome assessments will include:
Modified Rankin Scale
Barthel Index
Lawton Physical Self Assessment Test (PSMS)
Lawton Instrumental Activities of Daily Living (IADL)
NIH Stroke Scale (NIHSS)
Telephone Interview Cognitive Status (TICS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improve Neurological Outcome following aSAH</measure>
    <time_frame>At time of discharge from hospital</time_frame>
    <description>Outcome assessments will include:
Modified Rankin Scale
Barthel Index
Lawton Physical Self Assessment Test (PSMS)
Lawton Instrumental Activities of Daily Living (IADL)
NIH Stroke Scale (NIHSS)
Telephone Interview Cognitive Status (TICS)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Sugar Pill, Hunt Hess Grade I-III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Good Grade (Hunt Hess I-III), n=15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiopronin, Hunt Hess Grade I-III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Good Grade (Hunt Hess I-III), n=15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiopronin, Hunt Hess Grade IV-V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Poor Grade (Hunt Hess IV-V), n=15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill, Hunt Hess Grade IV-V</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Poor Grade (Hunt Hess IV-V), n=15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiopronin</intervention_name>
    <description>Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.</description>
    <arm_group_label>Tiopronin, Hunt Hess Grade I-III</arm_group_label>
    <arm_group_label>Tiopronin, Hunt Hess Grade IV-V</arm_group_label>
    <other_name>IUPAC Name:2-(2-sulfanylpropanoylamino)acetic acid</other_name>
    <other_name>CAS Number: 1953-02-2</other_name>
    <other_name>Thiola</other_name>
    <other_name>Thiopronin</other_name>
    <other_name>Thiosol</other_name>
    <other_name>Tioglis</other_name>
    <other_name>Acadione</other_name>
    <other_name>Capen</other_name>
    <other_name>Captimer</other_name>
    <other_name>Epatiol</other_name>
    <other_name>Vincol</other_name>
    <other_name>Mucolysin</other_name>
    <other_name>Sutilan</other_name>
    <other_name>Meprin (detoxicant)</other_name>
    <other_name>Thiolpropionamidoacetic acid</other_name>
    <other_name>N-2-Mercaptopropionyl glycine</other_name>
    <other_name>2-(2-sulfanylpropanoylamino)ethanoic acid</other_name>
    <other_name>2-(2-sulfanylpropanoylamino)acetic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.</description>
    <arm_group_label>Sugar Pill, Hunt Hess Grade I-III</arm_group_label>
    <arm_group_label>Sugar Pill, Hunt Hess Grade IV-V</arm_group_label>
    <other_name>placebo, sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to a recruiting center with aneurysmal subarachnoid hemorrhage

          -  Ability to initiate study drug treatment within 96 hours of aSAH onset.

          -  Ability to provide either informed or surrogate consent

        Exclusion Criteria:

          -  Hypersensitivity to penicillamine

          -  Creatinine level greater than 1.5/mm^3 on admission

          -  Platelet count of less than 100,000/mm^3 on admission

          -  White blood cell count of less than 3.5/mm^3 on admission

          -  AST or ALT of greater than 60/L on admission or history of liver failure

          -  Pregnancy

          -  History of lupus, Goodpasture's syndrome, myasthenia gravis, pemphigus, nephrotic
             syndrome, glomerulonephritis, or renal failure

          -  Patients considered unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E Sander Connolly, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Hoh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louis Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>96104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.columbianeurosurgery.org/</url>
    <description>The Columbia University Medical Center Department of Neurosurgery Website</description>
  </link>
  <link>
    <url>http://www.neurosurgery.ufl.edu/</url>
    <description>The University of Florida Department of Neurosurgery Website</description>
  </link>
  <link>
    <url>http://depts.washington.edu/neurosur/</url>
    <description>The University of Washington Department of Neurosurgery Website</description>
  </link>
  <link>
    <url>http://www.columbianeurosurgery.org/doctors/e-sander-connolly-jr/</url>
    <description>Principle Investigator: E. Sander Connolly Jr.</description>
  </link>
  <link>
    <url>http://www.columbianeurosurgery.org/research/research-laboratories/cerebrovascular-research-laboratory/</url>
    <description>Connolly Cerebrovascular Research Laboratory</description>
  </link>
  <reference>
    <citation>Linn FH, Rinkel GJ, Algra A, van Gijn J. Incidence of subarachnoid hemorrhage: role of region, year, and rate of computed tomography: a meta-analysis. Stroke. 1996 Apr;27(4):625-9.</citation>
    <PMID>8614919</PMID>
  </reference>
  <reference>
    <citation>Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke. 1997 Mar;28(3):660-4. Review.</citation>
    <PMID>9056628</PMID>
  </reference>
  <reference>
    <citation>Mayer S, Kreiter K. Quality of life after subarachnoid hemorrhage. J Neurosurg. 2002 Sep;97(3):741-2; author reply 742.</citation>
    <PMID>12296671</PMID>
  </reference>
  <reference>
    <citation>Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985 Jul-Aug;16(4):562-72. Review.</citation>
    <PMID>3895589</PMID>
  </reference>
  <reference>
    <citation>Solenski NJ, Haley EC Jr, Kassell NF, Kongable G, Germanson T, Truskowski L, Torner JC. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med. 1995 Jun;23(6):1007-17.</citation>
    <PMID>7774210</PMID>
  </reference>
  <reference>
    <citation>Shohami E, Nates JL, Glantz L, Trembovler V, Shapira Y, Bachrach U. Changes in brain polyamine levels following head injury. Exp Neurol. 1992 Aug;117(2):189-95.</citation>
    <PMID>1499692</PMID>
  </reference>
  <reference>
    <citation>Ivanova S, Botchkina GI, Al-Abed Y, Meistrell M 3rd, Batliwalla F, Dubinsky JM, Iadecola C, Wang H, Gregersen PK, Eaton JW, Tracey KJ. Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. J Exp Med. 1998 Jul 20;188(2):327-40.</citation>
    <PMID>9670045</PMID>
  </reference>
  <reference>
    <citation>Doğan A, Rao AM, Hatcher J, Rao VL, Başkaya MK, Dempsey RJ. Effects of MDL 72527, a specific inhibitor of polyamine oxidase, on brain edema, ischemic injury volume, and tissue polyamine levels in rats after temporary middle cerebral artery occlusion. J Neurochem. 1999 Feb;72(2):765-70.</citation>
    <PMID>9930751</PMID>
  </reference>
  <reference>
    <citation>Seiler N. Polyamine oxidase, properties and functions. Prog Brain Res. 1995;106:333-44. Review.</citation>
    <PMID>8584670</PMID>
  </reference>
  <reference>
    <citation>Ivanova S, Batliwalla F, Mocco J, Kiss S, Huang J, Mack W, Coon A, Eaton JW, Al-Abed Y, Gregersen PK, Shohami E, Connolly ES Jr, Tracey KJ. Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5579-84. Epub 2002 Apr 9.</citation>
    <PMID>11943872</PMID>
  </reference>
  <reference>
    <citation>Cockroft KM, Meistrell M 3rd, Zimmerman GA, Risucci D, Bloom O, Cerami A, Tracey KJ. Cerebroprotective effects of aminoguanidine in a rodent model of stroke. Stroke. 1996 Aug;27(8):1393-8.</citation>
    <PMID>8711808</PMID>
  </reference>
  <reference>
    <citation>Wood PL, Khan MA, Moskal JR. Neurochemical analysis of amino acids, polyamines and carboxylic acids: GC-MS quantitation of tBDMS derivatives using ammonia positive chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):313-9. Epub 2006 Jan 10.</citation>
    <PMID>16406747</PMID>
  </reference>
  <reference>
    <citation>Wood PL, Khan MA, Moskal JR, Todd KG, Tanay VA, Baker G. Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res. 2006 Nov 29;1122(1):184-90. Epub 2006 Oct 5.</citation>
    <PMID>17026969</PMID>
  </reference>
  <reference>
    <citation>Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980 Jan;6(1):1-9.</citation>
    <PMID>7354892</PMID>
  </reference>
  <reference>
    <citation>Lindell A, Denneberg T, Hellgren E, Jeppsson JO, Tiselius HG. Clinical course and cystine stone formation during tiopronin treatment. Urol Res. 1995;23(2):111-7.</citation>
    <PMID>7676533</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <disposition_first_submitted>January 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 28, 2014</disposition_first_posted>
  <last_update_submitted>June 15, 2016</last_update_submitted>
  <last_update_submitted_qc>June 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>E. Sander Connolly</investigator_full_name>
    <investigator_title>Professor of Neurological Surgery</investigator_title>
  </responsible_party>
  <keyword>aneurysm</keyword>
  <keyword>aneurysmal</keyword>
  <keyword>subarachnoid</keyword>
  <keyword>hemorrhage</keyword>
  <keyword>haemorrhage</keyword>
  <keyword>neuroprotection</keyword>
  <keyword>3-aminopropanal</keyword>
  <keyword>3AP</keyword>
  <keyword>polyamine oxidase</keyword>
  <keyword>spermine</keyword>
  <keyword>spermidine</keyword>
  <keyword>vasospasm</keyword>
  <keyword>cerebral ischemia</keyword>
  <keyword>neurosurgery</keyword>
  <keyword>neurological intensive care unit</keyword>
  <keyword>NICU</keyword>
  <keyword>Tiopronin</keyword>
  <keyword>Thiola</keyword>
  <keyword>FDA</keyword>
  <keyword>Thiopronin</keyword>
  <keyword>Thiosol</keyword>
  <keyword>Tioglis</keyword>
  <keyword>Acadione</keyword>
  <keyword>Capen</keyword>
  <keyword>Captimer</keyword>
  <keyword>Epatiol</keyword>
  <keyword>Vincol</keyword>
  <keyword>Mucolysin</keyword>
  <keyword>Sutilan</keyword>
  <keyword>Meprin</keyword>
  <keyword>Thiolpropionamidoacetic acid</keyword>
  <keyword>Mercaptopropionyl glycine</keyword>
  <keyword>2 MPG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
    <mesh_term>Retinol acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

